Physician profile
Minal Shah
NPI 1265683171
$15,230.81
in general payments reported to CMS, 2019-2025
69 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $1,049 · 2021: $3,017 · 2022: $2,029 · 2023: $3,378 · 2024: $2,363 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,040 · Consulting Fee: $1,575 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,039.64 |
| Consulting Fee | $1,575.00 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,048.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,776.99 | 2020-2024 | Jemperli, Zejula |
| Janssen Biotech, INC. | $1,488.37 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Pfizer INC. | $885.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $698.85 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $565.00 | 2019-2024 | Opdivo, Krazati |
| Merck Sharp & Dohme LLC | $522.18 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Seagen INC. | $495.61 | 2019-2023 | Tukysa, Padcev |
| Lilly USA, LLC | $378.35 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $347.56 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
| Genzyme Corporation | $310.52 | 2020-2025 | |
| Eisai INC. | $308.88 | 2019-2025 | |
| Puma Biotechnology, INC. | $295.48 | 2019-2025 | |
| Amgen INC. | $286.13 | 2019-2023 | Lumakras, Nplate |
| Incyte Corporation | $246.81 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $217.06 | 2020-2025 | Xpovio |
| Emd Serono, INC. | $201.86 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $190.00 | 2021-2025 | Libtayo |
| Coherus Oncology, INC. | $188.65 | 2021-2025 | Loqtorzi, Udenyca |
| Exelixis INC. | $183.52 | 2020-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $177.91 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $175.32 | 2020-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $165.21 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Abbvie INC. | $160.51 | 2019-2022 | |
| Taiho Oncology, INC. | $150.44 | 2023-2025 | |
| Daiichi Sankyo INC. | $146.38 | 2020-2025 | Datroway, Enhertu, Injectafer |
| Gilead Sciences, INC. | $145.30 | 2019-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $137.54 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $135.83 | 2019-2025 | Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.59 | 2019-2025 | |
| Astellas Pharma US INC | $123.83 | 2022-2025 | Padcev, Xospata, Vyloy |
| Mirati Therapeutics, INC. | $121.35 | 2023-2024 | Krazati |
| Array Biopharma INC | $118.03 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Kite Pharma, INC. | $113.69 | 2020-2023 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $107.09 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $98.71 | 2019-2024 | Somatuline Depot, Onivyde, Tazverik |
| Sobi, INC | $91.67 | 2022-2025 | |
| Foundation Medicine, INC. | $91.13 | 2019-2023 | |
| Tersera Therapeutics LLC | $90.60 | 2021-2024 | Xermelo |
| Pharmacosmos Therapeutics INC. | $80.98 | 2024-2025 | Monoferric |
| Clovis Oncology, INC. | $69.42 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $69.17 | 2022-2025 | |
| Genmab U.S., INC. | $64.27 | 2024-2025 | Epkinly |
| G1 Therapeutics, INC. | $61.30 | 2022 | |
| Pharmaessentia USA Corporation | $56.30 | 2022-2023 | Besremi |
| Legend Biotech USA INC. | $55.52 | 2025 | Carvykti |
| Myriad Genetic Laboratories, INC. | $54.99 | 2020-2021 | |
| Beone Medicines USA, INC. | $50.65 | 2025 | Tevimbra, Brukinsa |
| Syndax Pharmaceuticals, INC. | $47.86 | 2025 | |
| Tempus Ai, INC | $44.86 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $43.32 | 2022 | |
| Adaptive Biotechnologies Corporation | $42.29 | 2024-2025 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $33.84 | 2020-2021 | |
| Myovant Sciences INC. | $30.08 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $29.60 | 2019-2025 | Valchlor |
| Amag Pharmaceuticals, INC. | $27.64 | 2021-2022 | |
| Tesaro, INC. | $26.66 | 2019 | |
| Accord Healthcare, INC. | $23.97 | 2025 | |
| Beigene USA, INC. | $23.26 | 2025 | Brukinsa |
| Eusa Pharma (US) LLC | $23.04 | 2022 | |
| Novocure INC. | $20.81 | 2025 | Optune Lua (Novottf-200t) |
| Caris Mpi, INC. | $20.38 | 2025 | Mi Cancer Seek |
| Acrotech Biopharma INC. | $19.08 | 2024 | Beleodaq |
| Blue Earth Diagnostics | $18.09 | 2019 | |
| Secura Bio, INC. | $15.39 | 2025 | Copiktra |
| Tolmar, INC. | $15.05 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $15.05 | 2025 | Rubraca |
| Lexicon Pharmaceuticals, INC. | $13.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.